Emmanuel Babeau - Sanofi ADR Independent Director
SNY Stock | USD 48.60 0.94 1.90% |
Director
Mr. Emmanuel Babeau has held the position of Independent Director of Sanofi S.A. since May 2, 2018. He is Member of the Audit Committee of the Company. Since April 2013, he was Deputy Chief Executive Officer in charge of Finance Legal Affairs of Schneider Electric, office renewed on April 25, 2017. He began his career at Arthur Andersen in late 1990. In 1993, he joined Pernod Ricard as an Internal Auditor. He was appointed Head of Internal Audit, Corporationrationrate Treasury and Consolidation in 1996. He subsequently held several executive positions at Pernod Ricard, notably outside France, among which he served as Finance and Administrative Director Spain subsidiary in 1997. In 2001, he rejoined Pernod Ricard headoffices in Paris to hold position of Vice President, Development, in charge of the integration of Seagram. Progressing fast, he was appointed CFO in 2003 and Group Deputy Managing Director of Finance in 2006, supervising Finance, Information Systems and Industry Administrations. He joined Schneider Electric in 2009 as Executive Vice President Finance and Member of the Management Board of Schneider Electric since 2018.
Age | 51 |
Tenure | 6 years |
Address | 46, avenue de la Grande Armée,, Paris, France, 75017 |
Phone | 33 1 53 77 40 00 |
Web | https://www.sanofi.com |
Sanofi ADR Management Efficiency
The company has Return on Asset of 0.0454 % which means that on every $100 spent on assets, it made $0.0454 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0727 %, implying that it generated $0.0727 on every 100 dollars invested. Sanofi ADR's management efficiency ratios could be used to measure how well Sanofi ADR manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to rise to 0.17 in 2024. Return On Assets is likely to rise to 0.08 in 2024. At this time, Sanofi ADR's Non Currrent Assets Other are fairly stable compared to the past year. Intangible Assets is likely to rise to about 77.3 B in 2024, whereas Total Assets are likely to drop slightly above 88.2 B in 2024.Similar Executives
Showing other executives | DIRECTOR Age | ||
Ulrich Schmidt | Alcoa Corp | 65 | |
Samuel Palmisano | Exxon Mobil Corp | 68 | |
Jack Bovender | Bank Of America | 74 | |
John Frank | Chevron Corp | 64 | |
Suzanne Sitherwood | Alcoa Corp | 60 | |
Julie Richardson | Alcoa Corp | N/A | |
Paul Walsh | McDonalds | 65 | |
Alex Gorsky | International Business Machines | 60 | |
Charles Gifford | Bank Of America | 72 | |
Marissa Mayer | Walmart | 44 | |
Timothy Flynn | Walmart | 64 | |
Margaret Georgiadis | McDonalds | 56 | |
Richard Daley | The Coca Cola | 75 | |
Robert Kotick | The Coca Cola | 57 | |
Samuel Nunn | The Coca Cola | 78 | |
Mark Fields | International Business Machines | 55 | |
Henrietta Fore | Exxon Mobil Corp | 67 | |
Kathryn Fuller | Alcoa Corp | 73 | |
Joseph Hooley | Exxon Mobil Corp | 63 | |
Jim Walton | Walmart | 65 | |
Dambisa Moyo | Chevron Corp | 52 |
Management Performance
Return On Equity | 0.0727 | ||||
Return On Asset | 0.0454 |
Sanofi ADR Leadership Team
Elected by the shareholders, the Sanofi ADR's board of directors comprises two types of representatives: Sanofi ADR inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sanofi. The board's role is to monitor Sanofi ADR's management team and ensure that shareholders' interests are well served. Sanofi ADR's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sanofi ADR's outside directors are responsible for providing unbiased perspectives on the board's policies.
Dominique Carouge, Executive Vice President - Head of Business Transformation Member of the Executive Committee | ||
Emmanuel Babeau, Independent Director | ||
Roy Papatheodorou, Executive Counsel | ||
Pascale Witz, Executive Vice President - Global Divisions & Strategic Commercial Development, Member of the Executive Committee and the Global Leadership Team | ||
Serge Weinberg, Chairman, Interim CEO, Chairman of Appointments and Governance Committee and Chairman of Strategy Committee | ||
Dieter Weinand, Executive Vice President Member of the Executive Board | ||
Sebastien Martel, Vice President - Investor Relations and Member of the Global Leadership Team | ||
Eva SchaeferJansen, Head Relations | ||
Fabienne Lecorvaisier, Director | ||
George Grofik, Vice President of Investor Relations | ||
Karen Linehan, Executive VP of Legal Affairs and General Counsel | ||
Klaus Pohle, Independent Director | ||
John Reed, President - Global Research & Development, Member of the Executive Committee | ||
Bernard Charles, Independent Director | ||
Melanie Lee, Independent Director | ||
Madeleine Roach, Executive Operations | ||
Pierre Chancel, Senior Marketing | ||
Christophe Babule, Director | ||
Bonnie Bassler, Director | ||
Thomas Suedhof, Independent Director | ||
Caroline Luscombe, Executive Vice President of Human Resources, Member of the Executive Committee | ||
Laurent Attal, Director | ||
JeanRene Fourtou, Independent Director | ||
JeanBaptiste Chatillon, CFO, Executive Vice President Member of the Executive Committee | ||
Josephine Fubara, Chief Care | ||
Christian Mulliez, Director | ||
Robert Castaigne, Independent Director | ||
Laurent Gilhodes, Principal Accounting | ||
Jerome Contamine, Executive Vice President - CFO, Member of the Executive Committee and Global Leadership Team | ||
Uwe Bicker, Independent Director | ||
Josep Catlla, Head Communications | ||
Claudie Haignere, Independent Director | ||
Olivier Brandicourt, CEO, Director and Member of Strategy Committee | ||
Paul Hudson, CEO Director | ||
Bruno Mnard, Chief officer | ||
Suresh Kumar, Executive Vice President - External Affairs, Member of the Executive Committee and Global Leadership Team | ||
Dante Beccaria, Global VP | ||
Kathleen Tregoning, Executive Vice President External Affairs; Member of the Executive Committee | ||
William Sibold, Executive Vice President Sanofi Genzyme; Member of the Executive Committee | ||
Peter Guenter, Executive Vice President - Global Commercial Operations, Member of the Executive Committee and the Global Leadership Team | ||
David Loew, Member of the Global LeaderShip Team, Senior Vice President - Commercial Operations Europe | ||
Muzammil Mansuri, Executive Vice President Strategy & Business Development, Member of the Executive Committee and the Senior Leadership Team | ||
Diane Souza, Independent Director | ||
Carole Piwnica, Independent Director | ||
Elias Zerhouni, President - Global Research & Development, Member of the Executive Committee and the Global Leadership Team | ||
Ameet Nathwani, Executive Vice President Group Chief Medical Officer, Member of the Executive Committee | ||
Philippe Luscan, Senior Vice President - Industrial Affairs, Member of the Executive Committee and the Global Leadership Team | ||
Roberto Pucci, Senior Vice President - Human Resources, Member of the Executive Committee and the Global Leadership Team | ||
DavidAlexandre Gros, Executive Vice President Chief Strategy Officer and Member of the Executive Committee | ||
Olivier Charmeil, Senior Vice President - Vaccines, Member of the Executive Committee and Global Leadership Team | ||
Igor Landau, Director | ||
Patrick Kron, Independent Director | ||
Stefan Oelrich, Executive Vice President - Diabetes & Cardiovascular, Member of the Executive Committee | ||
Gerard Kemmel, Independent Director | ||
SuetFern Lee, Independent Director | ||
Carsten Hellmann, Executive Vice President - Animal Health and Member of the Global Leadership Team | ||
David Meeker, Member of the Executive Board and Executive Vice President - Genzyme and Member of the Global Leadership Team | ||
Alan Main, Executive Vice President Consumer Healthcare; Member of the Executive Committee | ||
Suet Lee, Independent Director |
Sanofi Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sanofi ADR a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.0727 | ||||
Return On Asset | 0.0454 | ||||
Profit Margin | 0.12 % | ||||
Operating Margin | 0.07 % | ||||
Current Valuation | 134.29 B | ||||
Shares Outstanding | 2.5 B | ||||
Shares Owned By Institutions | 9.94 % | ||||
Number Of Shares Shorted | 4.59 M | ||||
Price To Earning | 7.78 X | ||||
Price To Book | 1.54 X |
Sanofi ADR Investors Sentiment
The influence of Sanofi ADR's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Sanofi. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Sanofi ADR's public news can be used to forecast risks associated with an investment in Sanofi. The trend in average sentiment can be used to explain how an investor holding Sanofi can time the market purely based on public headlines and social activities around Sanofi ADR. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Sanofi ADR's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Sanofi ADR's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Sanofi ADR's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Sanofi ADR.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Sanofi ADR in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Sanofi ADR's short interest history, or implied volatility extrapolated from Sanofi ADR options trading.
Currently Active Assets on Macroaxis
When determining whether Sanofi ADR offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sanofi ADR's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sanofi Adr Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sanofi Adr Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sanofi ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Sanofi Stock please use our How to Invest in Sanofi ADR guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Complementary Tools for Sanofi Stock analysis
When running Sanofi ADR's price analysis, check to measure Sanofi ADR's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sanofi ADR is operating at the current time. Most of Sanofi ADR's value examination focuses on studying past and present price action to predict the probability of Sanofi ADR's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sanofi ADR's price. Additionally, you may evaluate how the addition of Sanofi ADR to your portfolios can decrease your overall portfolio volatility.
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Transaction History View history of all your transactions and understand their impact on performance | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Fundamental Analysis View fundamental data based on most recent published financial statements |
Is Sanofi ADR's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sanofi ADR. If investors know Sanofi will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sanofi ADR listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.217 | Dividend Share 3.76 | Earnings Share 2.33 | Revenue Per Share 18.388 | Quarterly Revenue Growth 0.029 |
The market value of Sanofi ADR is measured differently than its book value, which is the value of Sanofi that is recorded on the company's balance sheet. Investors also form their own opinion of Sanofi ADR's value that differs from its market value or its book value, called intrinsic value, which is Sanofi ADR's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sanofi ADR's market value can be influenced by many factors that don't directly affect Sanofi ADR's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sanofi ADR's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sanofi ADR is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sanofi ADR's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.